Lupin gets USFDA approval for Atorvastatin Calcium Tablets

Tablets indicated to lower cholesterol in blood for adults and children over 10 years of age.

Mar 08, 2019 08:03 IST India Infoline News Service

Lupin in its press note to the exchanges informed that the United States Food and Drug Administration (USFDA) granted approval to market Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg in the US.

Lupin's Atorvastatin Calcium Tablets USP 10 mg, 20 mg, 40 mg, and 80 mg, is the generic version of Pfizer Inc's Lipitor Tablets, 10 mg, 20 mg, 40 mg, and 80 mg, the company said in press note after markets hours to the exchanges on Thursday.

These are indicated to lower cholesterol in blood for adults and children over 10 years of age. Atorvastatin is also prescribed to lower the risk for heart attack, stroke in patients with cardiovascular diseases, diabetes and other risk factors such as eye problems, kidney diseases or high blood pressure.

According to IQVIA MAT data released in December 2018 Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg had annual sales of ~$696mn in the US.

Lupin Ltd's share price ended at Rs791.10, up by Rs2.45 or 0.31%, from its previous close of Rs788.65 on the BSE.
The scrip opened at Rs788 and touched a high and low of Rs803.10 and Rs786.50, respectively. A total of, 19,50,699 (NSE+BSE) shares have been traded on the counter. The current market cap of the company is Rs35,795.95cr.

Related Story

Open Free Demat Account (Rs699)